Literature DB >> 3655386

Isolation of low-frequency class-switch variants from rat hybrid myelomas.

G Hale1, S P Cobbold, H Waldmann, G Easter, P Matejtschuk, R R Coombs.   

Abstract

Class-switch variants have been isolated from rat-rat hybrid myelomas by sib selection using a simple assay based on red cell-labelled antiglobulins. The variants detected are consistent with the gene order deduced from molecular cloning. They appear to arise spontaneously at a rate approximately ten-fold lower than for mouse cell lines but the rate of switching back to the parental isotype is substantial in comparison. An IgG2b variant antibody having the same specificity as CAMPATH-1 for human lymphocytes and monocytes is active in antibody-dependent cell-mediated killing (unlike the parental IgG2a) and may prove to be a valuable therapeutic antibody for immunosuppression and treatment of leukaemia and lymphoma.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3655386     DOI: 10.1016/0022-1759(87)90242-0

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  15 in total

1.  Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice.

Authors:  Michio Tomura; Tetsuya Honda; Hideaki Tanizaki; Atsushi Otsuka; Gyohei Egawa; Yoshiki Tokura; Herman Waldmann; Shohei Hori; Jason G Cyster; Takeshi Watanabe; Yoshiki Miyachi; Osami Kanagawa; Kenji Kabashima
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

2.  Role for the class A macrophage scavenger receptor in the phagocytosis of apoptotic thymocytes in vitro.

Authors:  N Platt; H Suzuki; Y Kurihara; T Kodama; S Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

3.  [Alemtuzumab: a further option for treatment of multiple sclerosis].

Authors:  T Menge; B C Kieseier; C Warnke; O Aktas; H-P Hartung
Journal:  Nervenarzt       Date:  2012-04       Impact factor: 1.214

Review 4.  CAMPATH: from concept to clinic.

Authors:  Herman Waldmann; Geoff Hale
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

5.  Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.

Authors:  W Rowan; J Tite; P Topley; S J Brett
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

6.  Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis.

Authors:  M Q Xia; G Hale; M R Lifely; M A Ferguson; D Campbell; L Packman; H Waldmann
Journal:  Biochem J       Date:  1993-08-01       Impact factor: 3.857

7.  Humanized monoclonal antibody CAMPATH-1H: myeloma cell expression of genomic constructs, nucleotide sequence of cDNA constructs and comparison of effector mechanisms of myeloma and Chinese hamster ovary cell-derived material.

Authors:  J S Crowe; V S Hall; M A Smith; H J Cooper; J P Tite
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

Review 8.  Translating costimulation blockade to the clinic: lessons learned from three pathways.

Authors:  Mandy L Ford; Christian P Larsen
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

9.  A personal history of the CAMPATH-1H antibody.

Authors:  Herman Waldmann
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 10.  Alemtuzumab in stem cell transplantation.

Authors:  Geoff Hale
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.